Treatment of white coat hypertension with metformin

International Heart Journal

Volumn 49, Issue 6, 2008, Pages 671-679

  Helvaci, Mehmet Rami ^a   Sevinc, Alper ^b   Camci, Celalettin ^b   Yalcin, Atilla ^c  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c MERSIN UNIVERSITY   (Turkey)

Author keywords

Dyslipidemia; Excess weight; Metformin; White coat hypertension

Indexed keywords

GLUCOSE; METFORMIN; ANOREXIGENIC AGENT; ANTIDIABETIC AGENT;

ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE; WEIGHT REDUCTION; WHITE COAT HYPERTENSION; CHEMICALLY INDUCED DISORDER; HYPERTENSION; METABOLIC SYNDROME X; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ANOREXIA; APPETITE DEPRESSANTS; BLOOD GLUCOSE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; OBESITY; OVERWEIGHT;

EID: 60249084751     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.671     Document Type: Article

References (25)

1. Ohkubo T, Asayama K, Kikuya M, et al. How many times should blood pressure be measured at home for better prediction of stroke risk? Ten-year follow-up results from the Ohasama study. J Hypertens 2004; 22: 1099-104.
2. Ugajin T, Hozawa A, Ohkubo T, et al. White-coat hypertension as a risk factor for the development of home hypertension: the Ohasama study. Arch Intern Med 2005; 165: 1541-6.
3. Nakashima T, Yamano S, Sasaki R, et al. White-coat hypertension contributes to the presence of carotid arteriosclerosis. Hypertens Res 2004; 27: 739-45.
4. Curgunlu A, Karter Y, Uzun H, et al. Hyperhomocysteinemia: an additional risk factor in white coat hypertension. Int Heart J 2005; 46: 245-54.
5. Helvaci MR, Kaya H, Seyhanli M, Cosar E. White coat hypertension is associated with a greater all-cause mortality. J Health Sci 2007; 53: 156-60.
6. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541-9.
7. Schmidt R, Horn E, Richards J, Stamatakis M. Survival after metformin-associated lactic acidosis in peritoneal dialysis - dependent renal failure. Am J Med 1997; 102: 486-8.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
9. O'Brien E, Asmar R, Beilin L, et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 821-48. (Review)
10. Helvaci MR, Seyhanli M. What a high prevalence of white coat hypertension in society! Intern Med 2006; 45: 671-4.
11. Hozawa A, Ohkubo T, Kikuya M, et al. Blood pressure control assessed by home, ambulatory and conventional blood pressure measurements in the Japanese general population: the Ohasama study. Hypertens Res 2002; 25: 57-63.
12. Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur J Intern Med 2004; 15: 348-57.
13. Helvaci MR, Kaya H, Yalcin A, Kuvandik G. Prevalence of white coat hypertension in underweight and overweight subjects. Int Heart J 2007; 48: 605-13.
14. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-105.
15. Verdecchia P, Staessen JA, White WB, Imai Y, O'Brien ET. Properly defining white coat hypertension. Eur Heart J 2002; 23: 106-9. (Review)
16. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-9.
17. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-4.
18. Riccio A, Del Prato S, Vigili de Kreutzenberg S, Tiengo A. Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin. Diabete Metab 1991; 17: 180-4.
19. Jackson RA, Hawa MI, Jaspan JB, et al. Mechanism of metformin action in non-insulin-dependent diabetes. Diabetes 1987; 36: 632-40.
20. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995; 11: S57-62.
21. Wu MS, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13: 1-8.
22. Chang CT, Chen YC, Fang JT, Huang CC. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 2002; 15: 398-402. (Review)
23. Gore DC, Jahoor F, Hibbert JM, DeMaria EJ. Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Ann Surg 1996; 224: 97-102.
24. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18: 779-84.
25. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf 1999; 20: 377-84.